(±)-Methotrexate

(±)-Methotrexate is the racemate of Methotrexate (HY-14519), Methotrexate (low dose; intraperitoneal injection; weekly) exerts anti-inflammatory effects by enhancing the extracellular adenosine signaling pathway mediated by ADORA2A and ADORA3 receptors, reducing leukocyte accumulation and TNF-α accumulation at inflammatory sites, while inducing liver fibrosis in hepatotoxin models via this pathway^[2].
(±)-Methotrexate is the racemate of Methotrexate, Methotrexate (3 mg/kg; p.o.; daily; days 21-35) induces pulmonary fibrosis in male C57BL/6J mice in a time-dependent manner^[4].
(±)-Methotrexate is the racemate of Methotrexate, Methotrexate (40 mg/kg; i.p.; single dose) induces hippocampal dysfunction in both FM3A-inoculated breast cancer mice and tumor-free healthy mice, including significant depression-like behaviors, cognitive impairment, reduced hippocampal neurogenesis, and upregulated expression of pro-inflammatory enzymes^[5].
(±)-Methotrexate is the racemate of Methotrexate, Methotrexate (MTX) (2 mg/kg; i.p.; once weekly for 5 consecutive weeks) is effective against Freund's complete adjuvant-induced arthritis^[6].
(±)-Methotrexate is the racemate of Methotrexate, Methotrexate (1 mg/kg, intraperitoneal injection, once a week for 5 weeks) combined with Curcumin (HY-N0005, 30 mg/kg and 100 mg/kg, intraperitoneal injection, three times a week for 5 weeks) exhibits remarkable anti-arthritic effects and protective activity against hematotoxicity^[6].